secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001370053-25-000002
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 7.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio licenses imsidolimab to Vanda for $15M upfront; BLA/MAA prep underway
--------------------------------------------------------------------------------

- Anaptys receives $10M upfront and $5M for drug supply; eligible for up to $35M in milestones and 10% royalty on net sales.
- Imsidolimab, an IL-36R antagonist, completed two global Phase 3 trials (GEMINI-1 and GEMINI-2) in Generalized Pustular Psoriasis.
- Vanda plans to begin BLA and MAA submissions in the US and EU in 2025, leveraging its rare disease and anti-inflammatory expertise.
- Positive Phase 3 data showed rapid disease clearance after single dose, maintained clear skin for at least 24 weeks with no safety signals.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000002/0001370053-25-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000137005325000002/anab-20250131.htm
  HTML page:      https://secwatch.observer/filing/0001370053-25-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer